150 likes | 288 Views
Adriana Maggi DOCENTE DI BIOTECNOLOGIE FARMACOLOGICHE CORSO DI LAUREA SPECIALISTICA IN BIOTECNOLOGIE DEL FARMACO Lezione 2. A NOVEL INITIATIVE TO PUT EUROPE AT THE FOREFRONT OF BIOPHARMACEUTICALS INNOVATION. IMI STRATEGIC AGENDA reducing medical needs
E N D
Adriana Maggi DOCENTE DI BIOTECNOLOGIE FARMACOLOGICHE CORSO DI LAUREA SPECIALISTICA IN BIOTECNOLOGIE DEL FARMACO Lezione 2
A NOVEL INITIATIVE TO PUT EUROPE AT THE FOREFRONT OF BIOPHARMACEUTICALS INNOVATION
IMI STRATEGIC AGENDA • reducing medical needs • Supporting breakthrough of novel therapeutic avenues • Harmonizing reductionistic and systemic approaches to drug research • Optimizing R&D process • Implementing new techniques and technologies
reducing medical needs • Reclassification of the etiology of important diseases and relative drugs on the basis of the molecular target • Coordinate R&D on rare and neglected diseases • Meeting therapeutic needs in gender and age related diseases
Supporting breakthrough of novel therapeutic avenues • Nuclear medicine and imaging-based approaches • Extracorporeal therapies (gene surgery, tumor vaccine, stem cell therapy, tissue engineering) • Health technologies • Immunotherapies • Nucleic acid therapies • Productiontechnologies of biologicals
Harmonizing reductionistic and systemic approaches to drug research • Receptor-based drug research • Signaling pathways-based drug research (dual action, multi target approach: define complexity of signalling pathways, cell specificity, intr-pathway connectivity…) • Metabolic network-based drug research ( artificial intelligence for data handling and robotics for data generation: nomenclature, data collection, defining systems of pharmacological interest, generate formats of comparable information with old drugs, set up pilot studies)
Optimizing R&D process • Reshaping clinical studies • Regulatory measures for novel therapeutics • Personalized medicine • Systematic integration of patients into drug development • Correlate preclinical and clinical studies
Implementing new techniques and technologies • Novel approaches in target research • API technology • Advanced formulations • Imaging • Increasing practicability of biobancks • Pharmacoinformatics to correlate in vivo, in vitro and in silico research
BIOTECNOLOGIE E FARMACOLOGIA • Identificare nuovi bersagli farmacologici • Screening di farmaci • Nuovi molecole terapeutiche
Identificare nuovi bersagli farmacologici • GENOMATICA • GENOMATICA FUNZIONALE • MODELLI DI MALATTIA
La GENOMATICA e la ricerca di nuovi farmaci
GENOMATICA: • studio del genoma* degli esseri viventi attraverso la mappatura o sequenziamento dei geni e lo studio della loro funzione • * Per genoma si intende l’intero contenuto in DNA di una cellula, geni e sequenze intrageniche incluse
genoma umano Il genoma umano è costituito da 3.000.000.000 di paia di basi Diviso in 24 sequenze lineari : i cromosomi di cui 22 sono autosomi e 2 sono i cromosomi sessuali Il DNA mitocondriale è circolare e ha le dimensioni di 16569 pb
Mappare i geni: • Storicamente attraverso la costruzione di mappe fisiche (identificare e ordinare marcatori lungo il cromosoma) • Attualmente con il sequenziamento
mappe fisiche costruite con: • restriction mapping • FISH (Fluorescent in situ hybridization) mapping • studigeneticidi ‘linkage’ • use of sequence tagget site (STS)